Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine

Medical Science Monitor

Volumn 19, Issue , 2013, Pages 916-926

  Fang, Yantian ^a,b   Yao, Qizhi ^a   Chen, Zongyou ^b   Xiang, Jianbin ^b   William, Fisher E ^a   Gibbs, Richard A ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; Genetics; Genomics; Molecular target; Pancreatic cancer; Personalized medicine

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; CHLORAMBUCIL; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN G1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DJ 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FORETINIB; GELATINASE A; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; IPILIMUMAB; MELPHALAN; MICRORNA; MITOMYCIN; MIXED LINEAGE LEUKEMIA PROTEIN; PIMASERTIB; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; SMAD4 PROTEIN; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA2; UNINDEXED DRUG; VASCULOTROPIN;

APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PERSONALIZED MEDICINE; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; NEOPLASM PROTEINS; ONCOGENES; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887350112     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889636     Document Type: Review

References (167)

1. Gerstein MB, Bruce C, Rozowsky JS et al: What is a gene, post-ENCODE? History and updated definition. Genome Res, 2007; 17: 669-81
2. Steinman RM, Moberg CL: A triple tribute to the experiment that transformed biology. J Exp Med, 1994; 179: 379-84
3. Avery O, MacLeod C, McCarty M: Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type Iii. J Exp Med, 1944; 79: 137-58
4. Watson JD, Crick FHC: A structure of deoxyribonucleic acid. Nature, 1953; 171: 964-67
5. Min Jou W, Haegeman G, Ysebaert M, Fiers W: Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein. Nature, 1972; 237: 82-88
6. Khorana HG, Agarwal KL, Buchi H et al: Studies on polynucleotides. 103. Total synthesis of the structural gene for an alanine transfer ribonucleic acid from yeast. J Mol Biol, 1972; 72: 209-17
7. Itakura K, Hirose T, Crea R et al: Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science, 1977; 198: 1056-63
8. Jackson D, Symons R, Berg P: Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA, 1972; 69: 2904-9
9. Lobban P, Kaiser A: Enzymatic end-to end joining of DNA molecules. J Mol Biol, 1973; 78: 453-71
10. Cohen S, Chang A, Boyer H, Helling R: Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA, 1973; 70: 3240-44
11. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA, 1977; 74: 5463-67
12. Maxam AM, Gilbert W: A new method for sequencing DNA. Proc Natl Acad Sci USA, 1977; 74: 560-64
13. Hutchison CA III, Phillips S, Edgell MH et al: Mutagenesis at a specific position in a DNA sequence. J Biol Chem, 1978; 253: 6551-60
14. Min Jou W, Haegeman G, Ysebaert M, Fiers W: Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein. Nature, 1972; 237: 82-88
15. Sanger F, Air GM, Barrell BG et al: Nucleotide sequence of bacteriophage phi X174 DNA. Nature, 1977; 265: 687-95
16. Mullis K, Faloona F, Scharf S et al: Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. 1986. Biotechnology, 1992; 24: 17-27
17. Fleischmann RD, Adams MD, White O et al: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science, 1995; 269: 496-512
18. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature, 2001;409(6822): 860-921
19. Venter JC, Adams MD, Myers EW et al: The sequence of the human genome. Science, 2001; 291: 1304-51
20. International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature, 2004; 431: 931-45
21. Osoegawa K, Mammoser AG, Wu C et al: A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res, 2001; 11: 483-96
22. International HapMap Consortium: A haplotype map of the human genome. Nature, 2005; 437: 1299-320
23. International HapMap Consortium: A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007: 449: 851-61
24. International HapMap Consortium: Integrating common and rare genetic variation in diverse human populations. Nature, 2010; 467: 52-58
25. Durbin RM, Altshuler DL, Durbin RM et al: A map of human genome variation from population-scale sequencing. Nature, 2010; 467: 1061-73
26. McVean GA, Altshuler DM, Durbin RM et al: An integrated map of genetic variation from 1,092 human genomes. Nature, 2012; 491: 56-65
27. Obama B: Genomics and personalized medicine act of 2006. Washington, DC: U.S. Congress. Clin Adv Hematol Oncol, 2007; 5: 39-40
28. President's Council of Advisors on Science Technology: Priorities for Personalised Medicine, 2008. http://www.whitehouse.gov/files/documents/ ostp/PCAST/pcast_report_v2.pdf. accessed on July 26, 2013
29. Brunicardi FC, Gibbs RA, Fisher W, Chen C: Overview of the molecular surgeon symposium on personalized genomic medicine and surgery. World J Surg, 2009; 33(4): 612-14
30. Brunicardi FC, Gibbs RA, Wheeler DA et al: Overview of the development of personalized genomic medicine and surgery. World J Surg, 2011; 35: 1693-99
31. Targeted Cancer Therapies. http://www.cancer.gov/cancertopics/factsheet/ Therapy/targeted. accessed June 13, 2013
32. Table of Pharmacogenomic Biomarkers in Drug Labels. http://www.fda. gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378. htm, accessed on June 13, 2013
33. Hartmann LC, Sellers TA, Schaid DJ et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 2001; 93: 1633-37
34. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I et al: Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther, 2011; 10: 3-8
35. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin, 2013; 63: 11-30
36. NCI/NIH. Pancreatic Cancer. http://www.cancer.gov/cancertopics/types/pancreatic. accessed on June14, 2013
37. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol, 2008; 3: 157-88
38. Hernandez J, Mullinax J, Clark W et al: Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg, 2009; 250: 76-80
39. Hingorani SR, Petricoin EF, Maitra A et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003; 4: 437-50
40. Hingorani SR, Wang L, Multani AS et al: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005; 7: 469-83
41. Jones S, Zhang X, Parsons DW et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008; 321: 1801-6
42. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med, 2004; 10: 789-99
43. Biankin AV, Waddell N, Kassahn KS et al: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012; 491: 399-405
44. Caldas C, Kern SE. 1995. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol, 1995; 18: 1-6
45. Tada M, Ohashi M, Shiratori Y et al: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology, 1996; 110: 227-31
46. Schonleben F, Qiu WL, Ciau NT: PIK-3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res, 2006; 12: 3851-55
47. Cheng JQ, Ruggeri B, KleinWM et al: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA,1996; 93: 3636-41
48. Schlieman MG, Fahy BN, Ramsamooj R, et al: Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer, 2003; 89: 2110-15
49. Calhoun ES, Jones JB, Ashfaq R et al: 2003. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol, 2003; 163: 1255-60
50. McCubrey JA, Steelman LS, Chappell WH et al: Roles of the Raf/MEK/ ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta, 2007; 1773: 1263-84
51. Whipple CA, Young AL, Korc M: A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene, 2012; 31: 2535-44
52. Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H: The Notch pathway in cancer: differentiation gone awry. Eur J Cancer, 2005; 41: 2620-29
53. Miyamoto Y, Maitra A, Ghosh B et al: Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 2003; 3: 565-76
54. Hu H, Zhou L, Awadallah A, Xin W: Significance of Notch1-signaling pathway in human pancreatic development and carcinogenesis. Appl Immunohistochem Mol Morphol, 2013; 21: 242-47
55. Feldmann G, Dhara S, Fendrich V et al: Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res, 2007; 67: 2187-96
56. Corcoran RB, Contino G, Deshpande V et al: STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res, 2011; 71: 5020-29
57. Huang C, Jiang T, Zhu L, et al: STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol, 2011; 38: 1637-44
58. el-Deiry WS, Tokino T, Velculescu VE et al: WAF1, a potential mediator of p53 tumor suppression. Cell, 1993; 75: 817-25
59. Harper JW, Adami GR, Wei N et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993; 75: 805-16
60. Xiong Y, Hannon GJ, Zhang H et al: p21 is a universal inhibitor of cyclin kinases. Nature, 1993; 366: 701-4
61. Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA, 1995; 92: 8493-97
62. Aloni-Grinstein R, Schwartz D, Rotter V: Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J, 1995; 14: 1392-401
63. Goi K, Takagi M, Iwata S et al: DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res, 1997; 57: 1895-902
64. Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 2001; 7: 683-94
65. Scarpa A, Capelli P, Mukai K et al: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol, 1993; 142: 1534-43
66. Iacobuzio-Donahue CA, Fu B, Yachida S et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol, 2009; 27: 1806-13
67. Hahn SA, Schutte M, Hoque AT et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 1996; 271: 350-53
68. Toga T, Nio Y, Hashimoto K et al: The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome. Anticancer Res, 2004; 24: 1173-78
69. Jansen M, Ten Klooster JP, Offerhaus GJ et al: LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev, 2009; 89: 777-98
70. Giardiello FM, Welsh SB, Hamilton SR et al: Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med, 1987; 316: 1511-14
71. Hezel AF, Kimmelman AC, Stanger BZ et al: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev, 2006; 20: 1218-49
72. Delpu Y, Hanoun N, Lulka, H et al: Genetic and epigenetic alterations in pancreatic carcinogenesis. Current Genomics, 2011; 12: 15-24
73. Su GH, Hilgers W, Shekher MC et al: Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res, 1998; 58: 2339-42
74. Al-Sukhni W, Joe S, Lionel AC et al: Identification of germline genomic copy number variation in familial pancreatic cancer. Hum Genet, 2012; 131: 1481-94
75. Willis JA, Olson SH, Orlow I et al: A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res, 2012; 18: 3942-51
76. Jones S, Zhang X, Parsons DW et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008; 321: 1801-6
77. Hruban RH: Tumors of the pancreas. In: Hruban RH, Pitman MB, Klimstra DS (eds). Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington DC. 2007
78. Collins MA, Bednar F, Zhang Y et al: Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest, 2012; 122: 639-53
79. Gollamudi R, Ghalib MH, Desai KK et al: Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs, 2010; 28: 641-49
80. O'Reilly T, McSheehy PM, Wartmann M et al: Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs, 2011; 22: 58-78
81. Cook N, Frese KK, Bapiro TE et al: Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med, 2012; 209: 437-44
82. Feldmann G, Fendrich V, McGovern K et al: An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther, 2008; 7: 2725-35
83. van der Heijden MS, Brody JR et al: In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res, 2005; 11: 7508-15
84. Chawla SP, Chua VS, Fernandez L et al: Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabineresistant metastatic pancreatic cancer. Mol Ther, 2010; 18: 435-41
85. Lu Z, Hu L, Evers S et al: Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics, 2004; 4: 3975-88
86. Qi T, Han J, Cui Y, Zong M et al: Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol, 2008; 61: 49-58
87. Mikuriya K, Kuramitsu Y, Ryozawa S et al: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol, 2007; 30: 849-55
88. Makawita S, Smith C, Batruch I et al: Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics, 2011; 10: M111.008599
89. Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM: Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J, 2010; 277: 4578-90
90. Chen JH, Ni RZ, Xiao MB et al: Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int, 2009; 8: 193-200
91. Nedjadi T, Kitteringham N, Campbell F et al: S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer, 2009; 101: 1145-54
92. Sitek B, Sipos B, Alkatout I et al: Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res, 2009; 8: 1647-56
93. Sekine H, Chen N, Sato K et al: S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochem Biophys Res Commun, 2012; 429: 214-19
94. McKinney KQ, Lee YY, Choi HS et al: Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J Proteomics, 2011; 74: 79-88
95. Shen J, Person MD, Zhu J et al: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res, 2004; 64: 9018-26
96. Cui Y, Zhang D, Jia Q, Li T et al: Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest, 2009; 27: 747-55
97. Ni XG, Zhou L, Wang GQ et al: The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med, 2008; 14: 582-89
98. Cui Y, Wu J, Zong M et al: Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer, 2009; 124: 1614-21
99. Xue YZ, Sheng YY, Liu ZL et al: Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol, 2013; 34: 895-99
100. Wang L, Gu F, Liu CY et al: High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol, 2013; 34: 853-58
101. Takadate T, Onogawa T, Fukuda T et al: Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer, 2013;132: 1368-82
102. Takadate T, Onogawa T, Fujii K, M et al: Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalinfixed paraffin-embedded tissue. Clin Proteomics, 2012; 9: 8
103. Song SP, Zhang SB, Li ZH et al: Reduced expression of Raf kinase inhibitor protein correlates with poor prognosis in pancreatic cancer. Clin Transl Oncol, 2012; 14: 848-52
104. Xu X, Wang Y, Chen J et al: High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg, 2012; 16: 1493-98
105. Mahajan K, Coppola D, Chen YA et al: Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol, 2012; 180: 1386-93
106. Piscuoglio S, Zlobec I, Pallante P et al: HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology, 2012; 60: 397-404
107. Kim H, Zhai G, Samuel SL et al: Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther, 2012; 11: 405-15
108. Bunger S, Laubert T, Roblick UJ, Habermann JK: Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol, 2011; 137: 375-89
109. Bloomston M, Zhou JX, Rosemurgy AS et al: Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res, 2006; 66: 2592-99
110. Zhao J, Simeone DM, Heidt D et al: Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res, 2006: 5: 1792-802
111. Yan L, Tonack S, Smith R et al: Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res, 2009; 8: 142-48
112. Pan S, Chen R, Brand RE et al: Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res, 2012; 11: 1937-48
113. Melle C, Ernst G, Escher N et al: Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem, 2007; 53: 629-35
114. Hwang TL, Liang Y, Chien KY, Yu JS: Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics, 2006; 6; 2259-72
115. Chung HW, Lim JB, Jang S et al: Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma Cancer Sci, 2012; 103: 1714-21
116. Dutta SK, Girotra M, Singla M et al: Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas, 2012; 41: 530-34
117. Srivastava SK, Bhardwaj A, Singh S et al: MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis, 2011; 32: 1832-39
118. Fiedler GM, Leichtle AB, Kase J et al: Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res, 2009; 15: 3812-19
119. Matsubara J, Honda K, Ono M et al: Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 2011;20: 160-71
120. Sun ZL, Zhu Y, Wang FQ et al: Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta, 2007; 1774: 764-71
121. Takano S, Sogawa K, Yoshitomi H et al: Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer, 2010; 103: 223-31
122. Lin Y, Goedegebuure PS, Tan MC et al: Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res, 2006; 5: 2169-76
123. Tomaino B, Cappello P, Capello M et al: Autoantibody signature in human ductal pancreatic adenocarcinoma. J. Proteome Res, 2007; 6: 4025-31
124. Chen R, Pan S, Yi EC et al: Quantitative proteomic profiling of pancreatic cancer juice. Proteomics, 2006; 6: 3871-79
125. Tian M, Cui YZ, Song GH et al: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer, 2008; 8: 241
126. Park JY, Kim SA, Chung JW et al: Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol, 2011; 137: 1229-38
127. Gronborg M, Bunkenborg J, Kristiansen TZ et al: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res, 2004; 3: 1042-55
128. Zhou L, Lu Z, Yang A et al: Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics, 2007; 7: 1345-55
129. Cizginer S, Turner B, Bilge AR et al: Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas, 2011; 40: 1024-28
130. Naito Y, Okabe Y, Nagayama M et al: Accuracy of differential diagnosis for pancreatic cancer is improved in the combination of RCAS1 and CEA measurements and cytology in pancreatic juice. Med Mol Morphol, 2011; 44: 86-92
131. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004; 116: 281-97
132. Gregory RI, Yan KP, Amuthan G et al: The microprocessor complex mediate the genesis of microRNAs. Nature, 2004; 432: 235-40
133. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001; 409: 363-66
134. Ambros V: The functions of animal microRNAs. Nature, 2004; 431: 350-55
135. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993; 75: 843-54
136. Bentwich I, Avniel A, Karov Y et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet, 2005; 37: 766-70
137. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005; 120: 15-20
138. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 2009; 19: 92-105
139. Esquela-Kerscher A, Slack FJ: Oncomirs microRNAs with a role in cancer. Nat Rev Cancer, 2006; 6: 259-69
140. Li M, Marin-Muller C, Bharadwaj U et al: MicroRNAs: control and loss of control in human physiology and disease. World J Surg, 2009; 33: 667-84
141. Zhang Y, Li M, Wang H et al: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg, 2009; 33: 698-709
142. Papaconstantinou IG, Manta A, Gazouli M et al: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas, 2013; 42: 67-71
143. Szafranska AE, Davison TS, John J et al: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 2007; 26: 4442-52
144. Schultz NA, Werner J, Willenbrock H et al: MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol, 2012; 25: 1609-22
145. Piepoli A, Tavano F, Copetti M, Mazza T et al: MiRNA expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One, 2012; 7: e33663
146. Frampton AE, Gall TM, Castellano L et al: Towards a clinical use of miRNAs in pancreatic cancer biopsies. Expert Rev Mol Diagn, 2013; 13: 31-34
147. Ohuchida K, Mizumoto K, Lin C et al: MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol, 2012; 19: 2394-402
148. Chen Z, Chen LY, Dai HY et al: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem, 2012; 113: 3229-35
149. Hamada S, Satoh K, Fujibuchi W et al: MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res, 2012; 10: 3-10
150. Ji Q, Hao X, Zhang M et al: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One, 2009; 4: e6816
151. Zhao G, Zhang J, Liu Y et al: MiR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKa1. Mol Cancer Ther, 2013; 12: 83-93
152. Prevot PP, Augereau C, Simion A et al: Let-7b and miR-495 stimulate differentiation and prevent metaplasia of pancreatic acinar cells by repressing HNF6. Gastroenterology, 2013; pii: S0016-5085(13)00748-8
153. Ren C, Chen H, Han C et al: Increased plasma microRNA and CD133/CK18-positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance. Oncol Lett, 2012; 4: 691-94
154. Wang J, Chen J, Chang P, LeBlanc A et al: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res, 2009; 2: 807-13
155. Liu J, Gao J, Du Y et al: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer, 2012; 131: 683-91
156. Giovannetti E, van der Velde A, Funel N et al: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR-211 in pancreatic cancer. PLoS One, 2012; 7: e49145
157. Frampton AE, Krell J, Jacob J et al: microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther, 2011; 11: 1837-42
158. Bao B, Ali S, Kong D, Sarkar SH, Wang Z et al: Anti-Tumor Activity of a Novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 2011; 6: e17850
159. Park JK, Lee EJ, Esau C, Schmittgen TD: Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas, 2009; 38: e190-99
160. Ardito CM, Gruner BM, Takeuchi KK et al: EGF receptor is required for KRASinduced pancreatic tumorigenesis. Cancer Cell, 2012; 22: 304-17
161. Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R: Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World J Gastroenterol, 2012; 18: 6226-34
162. Boeck S, Jung A, Laubender RP et al: EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer, 2013; 108: 469-76
163. El-Mesallamy HO, Hamdy NM, Zaghloul AS, Sallam AM: Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis. Pancreas, 2013; 42: 149-54
164. Tomizawa M, Shinozaki F, Sugiyama T et al: Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol, 2010; 16: 1854-58
165. Tanemura M, Miyoshi E, Nagano H et al: Role of a-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer. Cancer Sci, 2013; 104: 282-90
166. Hardacre JM, Mulcahy M, Small W et al: Addition of Algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg, 2013; 17: 94-100
167. Royal RE, Levy C, Turner K et al: Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother, 2010; 33: 828-33